Grassroots Funding Imperative for Childhood Cancer Research
- OPACC
- Dec 28, 2016
- 1 min read
For adult cancer, over 50% of funding for drug development comes from pharmaceutical companies. For kids, that percentage is almost 0. Childhood cancer is complicated due to the growing minds and bodies of these young patients. They are also not profitable considering the low percentage of the population that children represent. Only 3 new childhood cancer drugs have been developed in the last 20 years compared to 120 new therapies approved for adults.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...